Skip to main content Accessibility help
×
Home

Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United States

  • Colleen S. Kraft (a1) (a2), Aneesh K. Mehta (a2), Jay B. Varkey (a2), G. Marshall Lyon (a2), Sharon Vanairsdale (a3), Sonia Bell (a2), Eileen M. Burd (a1), Mary Elizabeth Sexton (a2), Leslie Anne Cassidy (a4), Patricia Olinger (a5), Kalpana Rengarajan (a5), Vanessa N. Raabe (a2) (a6), Emily Davis (a3), Scott Henderson (a3), Paula DesRoches (a7), Yongxian Xu (a2), Mark J. Mulligan (a2) and Bruce S. Ribner (a2)...

Abstract

Objective:

Healthcare personnel (HCP) were recruited to provide serum samples, which were tested for antibodies against Ebola or Lassa virus to evaluate for asymptomatic seroconversion.

Setting:

From 2014 to 2016, 4 patients with Ebola virus disease (EVD) and 1 patient with Lassa fever (LF) were treated in the Serious Communicable Diseases Unit (SCDU) at Emory University Hospital. Strict infection control and clinical biosafety practices were implemented to prevent nosocomial transmission of EVD or LF to HCP.

Participants:

All personnel who entered the SCDU who were required to measure their temperatures and complete a symptom questionnaire twice daily were eligible.

Results:

No employee developed symptomatic EVD or LF. EVD and LF antibody studies were performed on sera samples from 42 HCP. The 6 participants who had received investigational vaccination with a chimpanzee adenovirus type 3 vectored Ebola glycoprotein vaccine had high antibody titers to Ebola glycoprotein, but none had a response to Ebola nucleoprotein or VP40, or a response to LF antigens.

Conclusions:

Patients infected with filoviruses and arenaviruses can be managed successfully without causing occupation-related symptomatic or asymptomatic infections. Meticulous attention to infection control and clinical biosafety practices by highly motivated, trained staff is critical to the safe care of patients with an infection from a special pathogen.

Copyright

Corresponding author

Author for correspondence: Colleen Kraft, MD, MSc, E-mail: colleen.kraft@emory.edu

Footnotes

Hide All
a

Emory Serious Communicable Diseases Unit: Administration: Catherine Maloney, Pam Cosper, Nancye Feistritzer, John Lewin, Bryce Gartland, Ira Horowitz, David Pugh, Chad Ritenour, Jerry Lewis, Brian Frislie, David Hatcher, Lynne Ometer, Kip Hardy. Nursing: Toni Ash, Christopher Barnes, Jamie Breedlove, Bob Bridgman, Lane Darragh, Tracey Daye, Dustin Hillis, Crystal Johnson, Julie-Ann Johnson, Danni LaFond, Courtney Lyons, Josia Mamora, Anna McCord, Samantha McDaniel, Haley Morgan, Jill Morgan, Alexander Sanchez, Marissa Simon, Jason Slabach, Kevin Tirado, Sally Watkins, Terrica Wilson, Ken Logan. Emory Medical Labs: Juli Buchanan, John Cardella, Brenda Eaves, Crystal Evans, Charles Hill, Doris Igwe, Karen Jenkins, Maureen Lindsey, Jordan Magee, Stacy McCarthy, Randall Powers, James Ritchie. Pharmacy: Jan Pack, Susan Rogers. Emory Health & Safety: Scott Thomaston, Esmeralda Meyer. Occupational Health: Cynthia Hall, Celeste Walker. Infection Prevention: Esther Baker, Betsy Hackman. Environmental Services: Jeff Broughton, Robert Jackson, Samantha Thomas. Pastoral Care: Robin Brown-Haithco, Faith Richardson. Emory Faculty and Staff Assistance: Art Krasilovsky, Clevevoya Jordan, Sue Matthews, Marilyn Hazzard Lineberger, Paula G. Gomes. Supplies/Logistics: Gentrice McGee, Porcia Jones. EUH Security: Linda Scott-Harris, James Cain, Roderick Davis, Tyrone Johnson, Tyrone Pickett, Anthony Shaw, Tenina Truesdale. Emergency Medical Services (EMS): Alex’Isakov, Sam Shartar, Wade Miles, Aaron Jamison, John Arevalo, Gail Stallings. Communications/Media Relations: Janet Christenbury, Vince Dollard, Melanie De Gennaro, Holly Korschun. Nutrition: Tom Ziegler, Daniel P. Griffith, Nisha Dave.

Footnotes

References

Hide All
1.WHO Ebola situation report. World Health Organization website. http://apps.who.int/ebola/en/current-situation/ebola-situation-report-6-may-2015, 2015. Published 2015. Accessed November 27, 2018.
2.Uyeki, TM, Mehta, AK, Davey, RT, Jr, et al.Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 2016;374:636646.
3.Hospital preparedness program. Public Health Emergency website. https://www.phe.gov/preparedness/planning/hpp/pages/default.aspx. Accessed December 9, 2019.
4.Kraft, CS, Hewlett, AL, Koepsell, S, et al.The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 2015;61:496502.
5.Liddell, AM, Davey, RT Jr, Mehta, AK, et al.Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med 2015;163:8190.
6.Lyon, GM, Mehta, AK, Varkey, JB, Brantly, K, Plyler, L, McElroy, AK, et al.Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014;371:24022409.
7.Raabe, VN, Kann, G, Ribner, BS, et al.Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis 2017;65:855859.
8.Beeching, NJ, Fenech, M, Houlihan, CF.Ebola virus disease, 2014. BMJ 2014;349:g7348.
9.Lowe, JJ, Olinger, PL, Gibbs, SG, et al.Environmental infection control considerations for Ebola. Am J Infect Control 2015;43:747749.
10.Bausch, DG, Towner, JS, Dowell, SF, et al.Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007;196 suppl 2:S142S147.
11.Clark, DV, Kibuuka, H, Millard, M, Wakabi, S, Lukwago, L, Taylor, A, et al.Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 2015;15:905912.
12.Bellan, SE, Pulliam, JR, Dushoff, J, Meyers, LA.Ebola control: effect of asymptomatic infection and acquired immunity. Lancet 2014;384:14991500.
13.Richardson, ET, Kelly, JD, Barrie, MB, et al.Minimally symptomatic infection in an Ebola ‘hotspot’: a cross-sectional serosurvey. PLoS Negl Trop Dis 2016;10(11):e0005087.
14.Mulangu, S, Alfonso, VH, Hoff, NA, et al.Serologic evidence of Ebolavirus infection in a population with no history of outbreaks in the Democratic Republic of the Congo. J Infect Dis 2018;217:529537.
15.Hewlett, AL, Varkey, JB, Smith, PW, Ribner, BS.Ebola virus disease: preparedness and infection control lessons learned from two biocontainment units. Curr Opin Infect Dis 2015;28:343348.
16.Isakov, A, Jamison, A, Miles, W, Ribner, B.Safe management of patients with serious communicable diseases: recent experience with Ebola virus. Ann Intern Med 2014;161:829830.
17.Lai, L, Davey, R, Beck, A, Xu, Y, Suffredini, AF, Palmore, T, et al.Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 2015;313:12491255.
18.Jacobs, M, Aarons, E, Bhagani, S, et al.Postexposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case series of healthcare workers. Lancet Infect Dis 2015;15:13001304.
19.Ledgerwood, JE, DeZure, AD, Stanley, DA, et al.Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med 2017;376:928938.
20.Houlihan, CF, McGowan, CR, Dicks, S, et al. Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014–2016: a cross-sectional study. PLoS Med 2017;14(5):e1002300.
21.Parham, M, Edison, L, Soetebier, K, et al.Ebola active monitoring system for travelers returning from West Africa to Georgia, 2014–2015. Morb Mortal Wkly Rep 2015;64:347350.
22.Smith, MW, Smith, PW, Kratochvil, CJ, Schwedhelm, S.The psychosocial challenges of caring for patients with Ebola virus disease. Health Secur 2017;15:104109.

Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United States

  • Colleen S. Kraft (a1) (a2), Aneesh K. Mehta (a2), Jay B. Varkey (a2), G. Marshall Lyon (a2), Sharon Vanairsdale (a3), Sonia Bell (a2), Eileen M. Burd (a1), Mary Elizabeth Sexton (a2), Leslie Anne Cassidy (a4), Patricia Olinger (a5), Kalpana Rengarajan (a5), Vanessa N. Raabe (a2) (a6), Emily Davis (a3), Scott Henderson (a3), Paula DesRoches (a7), Yongxian Xu (a2), Mark J. Mulligan (a2) and Bruce S. Ribner (a2)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed